Research programme: AstraZeneca 4 Programs - AstraZeneca and Pieris Pharmaceuticals

Drug Profile

Research programme: AstraZeneca 4 Programs - AstraZeneca and Pieris Pharmaceuticals

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pieris Pharmaceuticals
  • Developer AstraZeneca; Pieris Pharmaceuticals
  • Class Lipocalins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Respiration disorders

Most Recent Events

  • 12 Jun 2017 Pieris Pharmaceuticals' collaboration with AstraZeneca gets clearance post-expiration of the Hart-Scott-Rodino Act waiting period
  • 03 May 2017 AstraZeneca enters into a collaboration with Pieris Pharmaceuticals for Respiratory disorders to develop Anticalin®-based inhaled treatments
  • 03 May 2017 Early research in Respiration disorders in United Kingdom (Inhalation) (Pieris Pharmaceuticals Pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top